Overall, there were no significant differences in terms of median age at symptom onset, percentage of female patients, or SCLC disease extent at cancer diagnosis, in all patients with SCLC and associated paraneoplastic neurological disorders (LEMS, OMS, LE, PCD, and SSN) in those who did or did not have SOX2 antibodies (Supplementary table 1, all P > .05). Here, SOX2 is linked to Lambert-Eaton myasthenic syndrome.